<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029533</url>
  </required_header>
  <id_info>
    <org_study_id>DW_LP3M002</org_study_id>
    <nct_id>NCT03029533</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, Parallel-group, Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following Subcutaneous Administration of DWJ108J in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of
      DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with
      prostate cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 99</time_frame>
    <description>AUC0-7, AUC7-28, AUC 0-42, AUCt, AUCinf</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DWJ108J (leuprolide acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ108J (leuprolide acetate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuplin DPS Inj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leuplin DPS Inj</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>DWJ108J, SC injection, once(Day1)</description>
    <arm_group_label>DWJ108J (leuprolide acetate)</arm_group_label>
    <other_name>DWJ108J</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Leuplin DPS Inj, SC injection, once(Day1)</description>
    <arm_group_label>Leuplin DPS Inj</arm_group_label>
    <other_name>Leuplin DPS Inj</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males ≥19 and ≤80 years of age at Screening.

          2. Subject with histologically proven adenocarcinoma of the prostate requiring androgen
             deprivation therapy

          3. An ECOG performance status grade of 0 to 2,

          4. 19kg/m2≤ Body Mass Index (BMI) ≤30kg/m2 at Screening.

        Exclusion Criteria:

          1. Confirmed Hormone refractory prostate cancer(HRPC)

          2. Has had history of bilateral orchiectomy, suprarenalectomy or hypophysectomy.

          3. Diagnosed pituitary adenoma

          4. Has a history of depression

          5. Has a risk of spinal cor d compression due to metastatic spinal cord injury.

          6. Has a severe urethratresia.

          7. Confirmed uncontrolled Congestive heart failure (CHF) within 6 months of Screening.

          8. Has a history of MI or any procedure with regard to coronary artery disease within 6
             months of Screening. (e.g., balloon angioplasty, coronary artery bypass graft)

          9. Has any severe concomitant disease that would interfere with the conduct of the study
             except for prostate cancer

         10. Has allergy history of leuprolide acetate, similar GnRH drugs or other medications
             (e.g., Aspirin, antibiotics) and/or has any allergic disease requiring treatment.

         11. Has received an investigational drug within 9 0days of Screening.

         12. Drug releasing is expected after administration of study drug, if subject received
             GnRH agonist for treatment of prostate cancer.

         13. Has other chemotherapy planned within 14weeks from administration of study drug,
             except for androgen deprivation therapy.

         14. Has no willing of using method of contraception throughout the study period.

         15. Systolic Blood Pressure &lt; 90mmHg and/or ≥160mmHg or Diastolic Blood Pressure &lt; 60mmHg
             and/or ≥100mmHg at Screening

         16. QTcF &gt;450msec at Screening ECG.

         17. HbA1c level is high the upper limit of normal of reference range.

         18. Serum AST, ALT or Creatinine &gt; 1.5times the upper limit of normal at Screening.

         19. Positive results of tests for hepatitis B, hepatitis C, HIV or syphilis.

         20. Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest of the subject.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

